Kite Pharma announced that the U.S. FDA accepted for priority review the BLA for axicabtagene ciloleucel for refractory aggressive non-Hodgkin lymphoma (NHL).
- 2016 Annual Report: Top 10 Pipelines 12,000 views
- 2015 Annual Report: Top 10 Pipelines 11,866 views
- Celgene Snaps Up Merck & Co.’s Giant Complex in New Jersey 9,800 views
- 2015 Annual Report: Top 100 Biotechnology Companies – The Acquisition Game 3,900 views